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Prevalence of Left Ventricular Diastolic Dysfunction in a
General Population
Tatiana Kuznetsova, MD, PhD; Lieven Herbots, MD, PhD; Begon˜a Lo´pez, PhD; Yu Jin, MD;
Tom Richart, MD, MBE; Lutgarde Thijs, MSc; Arantxa Gonza´lez, PhD;
Marie-Christine Herregods, MD, PhD; Robert H. Fagard, MD, PhD;
Javier Díez, MD, PhD; Jan A. Staessen, MD, PhD
Background—Because the process of myocardial remodelling starts before the onset of symptoms, recent heart failure
(HF) guidelines place special emphasis on the detection of subclinical left ventricular (LV) systolic and diastolic
dysfunction and the timely identification of risk factors for HF. Our goal was to describe the prevalence and
determinants (risk factors) of LV diastolic dysfunction in a general population and to compare the amino terminal
probrain natriuretic peptide level across groups with and without diastolic dysfunction.
Methods and Results—In a randomly recruited population sample (n539; 50.5% women; mean age, 52.5 years), we
measured early and late diastolic peak velocities of mitral inflow (E and A), pulmonary vein flow by pulsed-wave
Doppler, and the mitral annular velocities (Ea and Aa) at 4 sites by tissue Doppler imaging. A healthy subsample of 239
subjects (mean age, 43.7 years) provided age-specific cutoff limits for normal E/A and E/Ea ratios and the differences
in duration between the mitral A and the reverse pulmonary vein flows during atrial systole (AdARd). The number
of subjects in diastolic dysfunction groups 1 (impaired relaxation), 2 (elevated LV end-diastolic filling pressure), and 3
(elevated E/Ea and abnormally low E/A) were 53 (9.8%), 76 (14.1%), and 18 (3.4%), respectively. We used(AdARd10)
to confirm possible elevation of LV filling pressures in group 2. Compared with subjects with normal diastolic function
(n392, 72.7%), group 1 (209 versus 251 pmol/L; P0.015) and group 2 (209 versus 275 pmol/L; P0.0003) but not
group 3 (209 versus 224 pmol/L; P0.65) had a significantly higher adjusted NT-probrain natriuretic peptide. Higher
age, body mass index, heart rate, systolic blood pressure, serum insulin, and creatinine were significantly associated with
a higher risk of LV diastolic dysfunction.
Conclusions—The overall prevalence of LV diastolic dysfunction in a random sample of a general population, as estimated
from echocardiographic measurements, was as high as 27.3%. (Circ Heart Fail. 2009;2:105-112.)
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Diastolic heart failure (HF) is a progressive disordercharacterized by impaired left ventricular (LV) relax-
ation, increased LV stiffness, increased interstitial deposition
of collagen, and modified extracellular matrix proteins. Dia-
stolic HF, also referred to as HF with normal ejection
fraction, currently accounts for 40% to 50% of all HF cases
and has a prognosis, which is as ominous as that of systolic
HF.1 With life expectancy increasing, HF is growing into a
major health problem. Because the process of myocardial
remodelling starts before the onset of symptoms, recent HF
guidelines2 place special emphasis on the detection of sub-
clinical LV systolic and diastolic dysfunction and the timely
identification of risk factors for HF.
Clinical Perspective see p 112
The echocardiographic techniques to assess early subclin-
ical changes in systolic and diastolic LV function evolved
rapidly over the past 10 years. New techniques of tissue
Doppler imaging (TDI) enable the measurement of myocar-
dial velocities and provide valuable information about LV
diastolic function in addition to classical M-mode and 2D
echocardiography and pulsed-wave Doppler. Presently, only
few population-based studies3,4 described the prevalence of
preclinical LV diastolic dysfunction, using the new TDI
indexes along with classical pulsed-wave Doppler velocities.
These studies applied a comprehensive Doppler analysis to
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grade LV diastolic dysfunction in older adults (aged 60 to 86
years)4 or in subjects aged 45 years or older.3 Age is an
important determinant of transmitral and myocardial Doppler
velocities. The prevalence of LV diastolic dysfunction in-
creased with age,5 but depended on applied arbitrary cutoff
levels. Taking into account the growing prevalence of HF,
our study aimed to describe the prevalence and determinants
(risk factors) of LV diastolic dysfunction in an unselected
general population. In addition, we compared the circulating
amino terminal probrain natriuretic peptide (NT-proBNP)
level across groups with and without diastolic dysfunction.
Methods
Study Participants
The Ethics Committee of the University of Leuven approved the
Flemish Study on Environment, Genes, and Health Outcomes
(FLEMENGHO).6 From August 1985 to December 2005, we iden-
tified a random population sample stratified by sex and age from a
geographically defined area in northern Belgium.6 Households,
defined as those who lived at the same address, were the sampling
unit. We numbered households consecutively, and generated a
random-number list by use of SAS random function. Households
with a number matching the list were invited; household members
older than 18 years were eligible. We reinvited 690 former partici-
pants for a follow-up examination at our field center, including
echocardiography. After excluding 20 patients who were bed-ridden
or institutionalized, we obtained informed written consent from 551
subjects (participation rate, 82%). We excluded a further 12 subjects,
because of atrial fibrillation (n6) or the presence of an artificial
pacemaker (n2), or because of diastolic function could not be
reliably determined (n4). Thus, the number of participants statis-
tically analyzed totaled 539 subjects.
Echocardiography
The participants refrained from smoking, heavy exercise, and drink-
ing alcohol or caffeine-containing beverages for at least 3 hours
before echocardiography. The blood pressure during echocardiography
was the average of 2 readings, obtained with a validated OMRON 705IT
device (Omron Corp, Tokyo, Japan) at the end of the examination.
Data Acquisition
One experienced physician (T.K.) did the ultrasound examination,7
using a Vivid7 Pro (GE Vingmed, Horten, Norway) interfaced with
a 2.5- to 3.5-MHz phased-array probe, according to the recommen-
dations of the American Society of Echocardiography.8 With the
subjects in partial left decubitus and breathing normally, the observer
obtained images, together with a simultaneous ECG signal, along the
parasternal long and short axes and from the apical 4- and 2-chamber
long-axis views. All recordings included at least 5 cardiac cycles and
were digitally stored for off-line analysis. M-mode echocardiograms
of the LV were recorded from the parasternal long-axis view under
control of the 2-dimensional image. The ultrasound beam was
positioned just below the mitral valve at the level of the posterior
chordae tendineae. To record mitral and pulmonary vein (PV) flow
velocities from the apical window and the isovolumetric relaxation
time (IVRT), the observer positioned the Doppler sample volume at
the mitral valve tips, in the right superior PV, and between the LV
outflow and mitral inflow, respectively.
Using TDI, the observer recorded low-velocity, high-intensity
myocardial signals at a high frame rate (190 FPS), whereas
adjusting the imaging angle to ensure a parallel alignment of the
ultrasound beam with the myocardial segment of interest. From the
apical window, the sonographer placed a 5 mm Doppler sample at
the septal, lateral, inferior and posterior sites of the mitral annulus.
Off-Line Analysis
Two sonographers analyzed digitally stored images, averaging 3
heart cycles for statistical analysis, using a workstation running the
EchoPac version 4.0.4 software package (GE Vingmed). The LV
internal diameter and interventricular septal and posterior wall
thickness were measured at end-diastole from the 2-dimensionally
guided M-mode tracing as described in the guidelines of the
American Society of Echocardiography.8 End-diastolic LV dimen-
sions were used to calculate LV mass by an anatomically validated
formula.8 Relative wall thickness was calculated as the ratio at
end-diastole of the thickness of interventricular septum plus posterior
wall to the LV internal diameter. LV end-systolic and end-diastolic
volumes and ejection fraction (EF) were calculated with the use of
Teicholtz’s method.
From the transmitral flow signal, we measured peak early diastolic
velocity (E), peak late diastolic velocity (A), the E/A ratio, and A
flow duration. From the PV flow signal, we measured the duration of
PV reversal time during atrial systole (AR). From the TDI record-
ings, we measured peak early (Ea) and peak late (Aa) diastolic mitral
annular velocities, and the Ea/Aa ratio at the 4 acquisition sites
(septal, lateral, inferior, and posterior).
To determine reproducibility, 2 experienced echocardiographists
(T.K. and L.H.) analyzed the recordings of 17 subjects. We determined
the absolute and relative biases between the 2 readers as well as 95%
limits of agreement between readers (Supplemental Figure A).
Other Measurements
At the examination center, trained study nurses administered a
questionnaire to collect detailed information on each subject’s
medical history, smoking and drinking habits, and intake of medi-
cations. NT-proBNP was measured in plasma samples by a compet-
itive enzyme immunoassay (EIA) for research use (Biomedica
Gruppe, Vienna, Austria).9 The standard range provided by the
manufacturer of the EIA is from 0 to 1000 pmol/L (median, 208
pmol/L; 95th, percentile 300 pmol/L). Hypertension was defined as
a blood pressure of at least 140 mm Hg systolic or 90 mm Hg
diastolic (average of 5 consecutive auscultatory readings at the
examination center) or as the use of antihypertensive drugs. Body
mass index was weight in kilograms divided by the square of height
in meters. Obesity was body mass index of 30 kg/m2 or higher.
Central obesity was waist circumference of at least 102 or 88 cm in
men and women, respectively. Diabetes was fasting blood glucose of
at least 6.7 mmol/L or use of insulin or oral antidiabetic agents. LV
hypertrophy was LV mass index of exceeding 125 g/m2 in men and
110 g/m2 in women. To generate a healthy reference sample, we
excluded participants if one or more of the following conditions were
present: hypertension (n182), diabetes (n11), obesity (n79),
central obesity (n108), LV hypertrophy (n43), or cardiac dis-
eases (valvular abnormalities, n25; myocardial infarction and/or
coronary revascularization, n15). The number of subjects in the
healthy reference group consisted of 239.
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Statistical Methods
For database management and statistical analysis, we used SAS
software version 9.1 (SAS Institute, Cary, NC). We compared means
and proportions by means of a large sample z-test and the 2 test,
respectively. We performed single and stepwise linear regression to
identify correlates of the Doppler indices as measured on a contin-
uous scale. We searched for variables associated with LV diastolic
dysfunction using stepwise logistic regression. We set the probability
values for variables to enter and to stay in the regression models at
0.05. We ran regression diagnostics to exclude the possibility that
collinearity might have inappropriately influenced our multivariate
models. We computed the variance inflation factor (VIF), Mallow
Cp, and the adjusted R2. The variance inflation factor measures to
what extent variance, standard error, parameter estimates are inflated
by introducing redundant highly intercorrelated explanatory vari-
ables in multiple regression models. Mallow Cp is a function of the
residual sum of squares of regression models with more or less
explanatory variables. The adjusted R2 expresses the goodness of fit
of the models. Higher adjusted R2 and lower Mallow Cp indicate a
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better model. In logistic regression, we used the option “RIDGING”
as implemented in the SAS package. We included in the logistic
model important anthropometric and hemodynamic characteristics
defined by stepwise selection (age, sex, body mass index, heart rate,
blood pressure, and antihypertensive treatment), physiologically
relevant biochemical parameters, such as serum insulin, serum
creatinine, NT-proBNP, and total cholesterol, and variables reflect-
ing cardiac structure that might influence LV diastolic function.
Results
Characteristics of Participants
The 539 participants included 272 (50.5%) women, and 221
(41.0%) hypertensive patients of whom 121 (23.6%) were on
antihypertensive drug treatment. Only 8 subjects (1.5%) had
EF equal or less than 50%. Ea, Ea/Aa, and E/Ea were higher
(P0.0001) at the lateral than at the other acquisition sites
(data not shown). Table 1 shows the clinical and echocardio-
graphic characteristics of the study participants in an entire
population and in a healthy reference group.
Determinants of Transmitral and TDI Doppler
Velocities in a General Population
In all subjects, the transmitral E/A ratio and the averaged
mitral annular Ea/Aa ratio both significantly and indepen-
dently decreased with age, body mass index, heart rate and
diastolic blood pressure (Table 2). Both ratios increased with
the pulse pressure. The transmitral E/A ratio, but not the
averaged Ea/Aa ratio increased with the EF. Furthermore, the
averaged E/Ea ratio significantly and independently increased
with female sex, age, body mass index, systolic blood
pressure, and LV mass index (Table 2). The explained
variance totaled 69.0% for the transmitral E/A ratio, 74.4%
for the averaged mitral annular Ea/Aa ratio and 51.0% for the
E/Ea ratio. Age accounted for most of the explained variance
(53.9%, 62.4%, and 34.2%, respectively).
Transmitral and TDI Doppler Indexes in 239
Healthy Subjects
Figure 1 shows age-specific percentiles of the E/A and E/Ea
ratios in the healthy subsample of 239 subjects (Supplemental
Table A). There was a significant decline in the E/A ratio
with age (P0.0001; Figure 1, left) because of a significant
decrease in E velocity as well as an increase in A velocity
(data not shown). The E/Ea ratio significantly increased with
age (P0.0001) in the reference group (Figure 1, right).
However, the 97.5% percentile of the E/Ea ratio in all ages
combined did not exceed the proposed cutoff limit of 8.5
for the normal filling pressure. In the reference group, the
(Ad–ARd) was not dependent on age. The 2.5% to 97.5%
percentiles interval ranged from –5.71 to 8.57, respectively
(Supplemental Table A).
Prevalence of LV Diastolic Dysfunction in the
Population Based on Age-Specific Doppler Criteria
We combined the Doppler measurements of the mitral inflow,
the reverse flow in the PV, and averaged TDI mitral annulus
velocities to determine stages of LV diastolic dysfunction.
The first group included subjects with an abnormally low
age-specific transmitral E/A ratio indicative of impaired
Table 1. Characteristics of Participants
Clinical Measurements Echocardiographic Measurements
Characteristic
Entire Population
(n539)
Healthy Reference
Group (n239) Characteristic
Entire Population
(n539)
Healthy Reference
Group (n239)
Anthropometrics Conventional echocardiography
Women 272 (50.5) 114 (47.7) Left atrium, cm 3.960.54 3.730.45
Age, years 52.415.3 43.712.9 LV internal diameter, cm 5.040.50 5.030.44
Height, cm 168.59.4 170.99.1 Interventricular septum, cm 0.990.18 0.910.14
Weight, kg 74.813.5 70.411.7 Posterior wall, cm 0.880.15 0.810.12
Body mass index, kg/m2 26.34.0 24.02.9 Relative wall thickness 0.370.074 0.340.055
Waist circumference, cm 88.611.5 82.49.4 LV mass index, g/m2 92.721.7 83.815.7
Systolic pressure, mm Hg 130.218.3 118.39.6 Ejection fraction, % 68.87.8 67.16.4
Diastolic pressure, mm Hg 79.29.2 75.16.9 Doppler data
Heart rate, beats/min 60.69.7 59.78.6 E peak, cm/s 75.816.3 79.915.5
Questionnaire data A peak, cm/s 66.617.7 56.812.7
Current smoking 116 (21.5) 71 (29.7) E/A ratio 1.230.46 1.480.46
Drinking alcohol 228 (42.3) 123 (51.5) Ea peak*, cm/s 11.43.67 13.83.13
Hypertensive 221 (41.0) . . . Aa peak*, cm/s 10.52.03 9.842.06
Treated for hypertension 121 (23.6) . . . Ea/Aa ratio* 1.180.59 1.530.62
Biochemical data E/Ea ratio 7.142.18 5.961.25
Serum creatinine, mol/l 85.815.7 83.611.8 IVRT, ms 101.515.6 97.713.0
NT-proBNP, pmol/L 229 (129–436) 214 (129–398) (Adur–ARdur), ms 0.4413.0 1.583.96
Insulin, U/mL 4.57 (1.99–11.0) 3.71 (1.99–7.94)
Data are presented as meanSD, n (%), or geometric mean (10% to 90% interval).
IVRT indicates isovolumetric relaxation time; Adur, mitral inflow A-wave duration; ARdur, pulmonary vein atrial reversal flow duration.
*Averaged of septum, lateral, inferior and posterior mitral annulus sites.
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relaxation (2.5th percentile of the reference subgroup;
Supplemental Table A), but without evidence of increased
LV filling pressures (E/Ea, 8.5). The second group had
mildly-to-moderately elevated end-diastolic filling pressure
with E/Ea 8.5, and E/A ratio within the normal age-specific
range (from 2.5th to 97.5th percentiles of the reference
subgroup; Supplemental Table A). We used the differences in
durations between the mitral A flow and the reverse PV flow
during atrial systole (AdARd10) to confirm possible
elevation of filling pressures in group 2. Group 3 had both an
elevated E/Ea ratio and an abnormally low age-specific E/A
(combined dysfunction). The number of subjects in groups 1,
2, and 3 were 53 (9.8%), 76 (14.1%), and 18 (3.4%),
respectively. Table 3 presents the prevalence of diastolic
dysfunction by age group. The clinical and echocardiographic
characteristics of subjects by group of diastolic function
appear in Tables 4 and 5, respectively. Compared with
subjects with normal diastolic function (n392, 72.7%),
those with elevated end-diastolic filling pressure had a
significantly higher sex-, age-, body mass index–, and serum
creatinine–adjusted NT-proBNP (209 versus 275 pmol/L;
P0.0003), with a similar trend (209 versus 251 pmol/L;
P0.015) for those with impaired relaxation (group 1). How-
ever, there was no statistical difference in NT-proBNP level
Table 2. Correlates of the Transmitral E/A, Averaged Mitral Annular Ea/Aa, and E/Ea Ratios in Stepwise
Regression in All Subjects
Parameter Transmitral E/A VIF Averaged TDI Ea/Aa VIF E/Ea VIF
R2 0.684 0.736 0.504
Adjusted R2 0.680 0.733 0.497
Root MSE 0.257 0.304 1.52
Mallow Cp 4.83 6.61 8.00
Partial regression coefficients
Age (10 years) 0.2300.010* 1.57 0.2920.011* 1.54 0.3870.064* 1.70
Female (0, 1) . . . 0.0570.027† 1.07 0.7140.189* 1.24
Body mass index (1 kg/m2) 0.0150.003* 1.26 0.0290.004* 1.23 0.0710.019* 1.20
Heart rate (10 beats/minute) 0.120.013* 1.08 0.0880.014* 1.14 . . .
Systolic BP (10 mm Hg) . . . . . . 0.3240.047* 1.60
Diastolic BP (10 mm Hg) 0.0690.015* 1.32 0.1040.017* 1.32 . . .
Pulse Pressure (10 mm Hg) 0.0310.010‡ 1.45 0.0460.011* 1.45 . . .
LV mass index (10 g/m2) . . . . . . 0.1720.041* 1.65
Ejection fraction (10%) 0.0470.016‡ 1.10 . . . . . .
Use of RAAS inhibitors (0, 1) . . . . . . 0.8440.285‡ 1.09
Use of -blockers (0, 1) . . . . . . 0.4870.212† 1.15
Values are mutually adjusted partial regression coefficientsSE.
MSE indicates mean squared error; BP, blood pressure; RAAS, renin-angiotensin-aldosterone system.
*P0.001; †P0.05; ‡P0.01.
Figure 1. Age-specific percentiles of the E/A (left) and E/Ea (right) ratios for the healthy reference sample (n239).
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between the group with normal diastolic function and group with
combined dysfunction (209 versus 224 pmol/L; P0.66).
Figure 2 shows the adjusted odds of having LV diastolic
dysfunction. Higher age, body mass index, heart rate, and
systolic blood pressure were significantly associated with a
higher risk of LV diastolic dysfunction. Use of -blockers
was weakly but positively associated with a higher risk of LV
diastolic dysfunction (95% CI, 0.98 to 3.84; P0.056). The
prevalence of diastolic dysfunction also increased with serum
insulin, serum creatinine and NT-proBNP.
Discussion
In this random sample of a general population, the overall
prevalence of LV diastolic dysfunction, as estimated from
echocardiographic measurements was as high as 27.3% and
increased in frequency with age. The reported prevalence of
Table 3. Age Distribution of the Total and Reference Samples and by Diastolic Function Group
Age Group (years)
30 30–39 40–49 50–59 60–69 70
Group
Total 55 (10.2) 49 (9.1) 131 (24.3) 131 (24.3) 99 (18.4) 74 (13.7)
Reference 45 (18.8) 36 (15.1) 81 (33.9) 53 (22.2) 19 (7.9) 5 (2.1)
Diastolic function
Normal function 52 (13.3) 47 (12.0) 120 (30.6) 104 (26.5) 52 (13.3) 17 (4.3)
Group 1: impaired relaxation 3 (5.7) 1 (1.9) 7 (13.2) 17 (32.1) 13 (24.5) 12 (22.6)
Group 2: elevated end-diastolic pressure . . . 1 (1.3) 3 (3.9) 8 (10.5) 27 (35.5) 37 (48.7)
Group 3: combined dysfunction . . . . . . 1 (3.6) 2 (11.1) 7 (38.9) 8 (44.4)
Data are presented as n (%). Impaired relaxation (group 1) indicates low E/A and normal E/Ea; elevated end-diastolic pressure
(group 2), normal E/A and high E/Ea; combined dysfunction (group 3), low E/A and high E/Ea.
Table 4. Clinical Characteristics of Participants by Diastolic Function Group
Characteristic
Normal Function
(n392)
Impaired Relaxation
(n53)
Elevated End-Diastolic Pressure
(n76)
Combined Dysfunction
(n18)
Transmitral E/A ratio Normal 2 Normal 2
E/Ea ratio Normal Normal 1 1
Age, years 47.613.6 60.214.0* 67.99.0*† 69.19.2*†
Women 187 (47.2) 23 (43.4) 48 (63.2)*† 14 (77.8)*†
Body mass index, kg/m2 25.53.6 28.03.8* 28.54.9* 29.52.6*
Systolic pressure, mm Hg 125.515.9 136.315.3* 146.618.9*† 147.119.2*†
Diastolic pressure, mm Hg 78.68.9 83.79.6* 77.89.7 83.87.9*‡
Heart rate, beats/minute 60.18.9 67.511.8* 57.59.2*† 64.910.1‡
Questionnaire data
Current smoking 91 (23.2) 14 (26.4) 10 (13.2) 1 (5.6)
Drinking alcohol 187 (47.7) 19 (35.8) 20 (26.3)* 2 (11.1)*†
Hypertensive 112 (28.6) 36 (67.9)* 59 (77.6)* 14 (77.8)*
Treated for hypertension 53 (13.5) 25 (47.2)* 41 (53.9)* 8 (44.4)*
-blockers 33 (8.4) 12 (22.6)* 29 (38.2)* 4 (22.2)*
ACE or ARB 15 (3.8) 12 (22.6)* 9 (11.8)* 2 (11.1)
Diuretics or CCB 26 (6.6) 10 (18.9)* 25 (32.9)* 5 (27.8)*
Cardiac valve disorder 7 (1.8) 3 (5.7) 13 (17.1)* 2 (11.1)
History of CHD 1 (0.26) 2 (3.8) 9 (11.8)* 1 (5.6)
Diabetes 5 (1.3) 1 (1.9) 3 (3.95) 2 (11.1)*
Biochemical data
NT-proBNP, pmol/L 214 (123 to 398) 269* (132 to 524) 302* (148 to 602) 245 (117 to 512)
Serum creatinine, mol/L 84.012.0 95.031.2* 88.214.7* 87.913.9
Insulin, U/mL 4.27 (2.0 to 8.91) 5.75* (3.02 to 12.9) 5.24* (3.02 to 10.0) 8.13*‡ (2.95 to 20.0)
Data are presented as meanSD, n (%), or geometric mean (10% to 90% interval).
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blockers; CCB, calcium channel blocker; CHD, coronary
heart disease.
*P0.05 versus normal; †P0.05 versus impaired relaxation group; ‡P0.05 versus elevated end-diastolic pressure group.
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diastolic dysfunction in the general population3,4,10,11 varies
from 11.1% to 34.7%, and is influenced by a number of
factors, including the characteristics of the population stud-
ied, the choice of the imaging modalities, and the criteria
applied to diagnosed LV diastolic dysfunction.
The gold standard for assessing diastolic function remains the
pressure-volume relationship, but this requires an invasive ap-
proach. Doppler measurements of mitral inflow and the TDI
technique open up the possibility of evaluating noninvasively
diastolic function.12 Even these techniques are complex because
no single measurement reflects diastolic function. Thus, a
comprehensive assessment of a number of variables is required
to evaluate diastolic function as correctly as possible.13 We
assessed LV diastolic function, using the transmitral and pulmo-
nary blood flows, and the TDI mitral annular velocities. Lower
transmitral E/A ratio and lower mitral annular Ea/Aa ratio both
reflect impaired myocardial relaxation, characterized by de-
creased early, but enhanced atrial filling of the LV. In keeping
with previous studies in the general population,4,14 we also
demonstrated that LV relaxation as reflected by both indexes
substantially decreased with age in all study participants and in
the healthy reference group. Current guidelines propose criteria
to diagnose diastolic dysfunction which are not standardized
for age.1,12 It is likely that by ignoring age and by applying
Table 5. Echocardiographic Characteristics of Participants by Diastolic Function Group
Characteristic
Normal
Function
(n392)
Impaired
Relaxation
(n53)
Elevated End-Diastolic
Pressure
(n76)
Combined
Dysfunction
(n18)
Transmitral E/A ratio Normal 2 Normal 2
E/Ea ratio Normal Normal 1 1
Conventional echocardiography
Left atrium diameter, cm 3.880.52 4.060.66 4.250.49* 4.140.47*
LV internal diameter, cm 5.030.45 5.070.65 5.050.62 4.850.42
Interventricular septum, cm 0.960.17 1.040.18* 1.080.17* 1.220.20*†‡
Posterior wall, cm 0.850.14 0.920.15* 0.960.14* 1.040.15*†
Relative wall thickness 0.360.07 0.390.08* 0.410.08* 0.450.07*†‡
LV mass index, g/m2 88.418.5 99.524.5* 107.025.5* 115.924.3*†
Ejection fraction, % 68.47.0 66.010.2 71.88.7*† 71.69.5
Transmitral doppler data
E peak, cm/s 78.314.9 53.818.9* 81.313.6† 63.016.4*†‡
A peak, cm/s 60.614.2 78.912.5* 82.216.1* 96.218.2*†‡
E/A ratio 1.370.44 0.700.15* 1.020.23*† 0.650.09*‡
IVRT, ms 98.313.2 114.916.4* 108.516.7*† 107.124.3
Adur-ARdur, ms 1.42 (2.9 to 7.1) 18.5* (1.42 to 32.1) 20.0*† (37.1 to 6.8) 19.2*‡ (12.8 to 31.4)
Tissue doppler velocities§
Ea peak, cm/s 12.73.27 8.281.93* 7.801.23* 5.941.02*†‡
Aa peak, cm/s 10.22.01 12.11.77* 10.51.88† 11.61.20*‡
Ea/Aa ratio 1.350.60 0.710.22* 0.770.19* 0.520.10*†‡
E/Ea ratio 6.371.34 6.661.11 10.62.09*† 10.72.30*†
Data are presented as meanSD or geometric mean (10% to 90% interval).
IVRT indicates isovolumetric relaxation time; Adur, mitral inflow A-wave duration; ARdur, pulmonary vein atrial reversal flow
duration.
*P0.05 versus normal; †P0.05 versus impaired relaxation group; ‡P0.05 versus elevated end-diastolic pressure group.
§Averaged of septum, lateral, inferior and posterior mitral annulus sites.
Figure 2. Association between diastolic
dysfunction and clinical and biochemical
characteristics. Black squares and horizon-
tal lines represent the odds ratios and 95%
CIs for the mutually adjusted covariates,
identified by stepwise regression.
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the same threshold values for the Doppler indexes through-
out the age range, one may underestimate the prevalence of
subclinical diastolic dysfunction (impaired relaxation),
especially in young subjects.
The Doppler blood flow measurements and the TDI mitral
annulus velocities can reflect abnormal LV relaxation as well
as elevated LV filling pressure. Combining transmitral flow
velocity with annular velocity (E/Ea ratio) might be a tool for
assessing the LV filling pressure, which combines the influ-
ence of the transmitral driving pressure and myocardial
relaxation.15,16 In our general population, only 6 subjects
(1.1%) had an E/Ea ratio in excess of the proposed threshold
of 15 as the diagnostic criteria for an elevated end-diastolic
pressure. The majority of patients with elevated LV end-di-
astolic filling pressure in the presence of normal EF (50%),
as determined in several previous studies by invasive
pressure-volume loops, had an E/Ea ratio between 8 and
15.15,17 Ommen et al15 suggested that the accurate prediction
of LV filling pressures for an individual patient requires a
further characterization of the intermediate E/Ea group, for
instance with PV flow information. In our study, we used the
difference in duration between the mitral A flow and the
reverse PV flow during atrial systole (AdARd10) to
confirm a possible elevation of filling pressures. Moreover,
we described one of the categories of diastolic dysfunction
(group 3) as having a low E/A ratio but an elevated E/Ea
ratio. To our knowledge, this is heretofore undescribed group
of patients. This implies that there is a significant relaxation
abnormality in the LV, such that both left atrial pressure and
LV diastolic pressure are elevated in parallel, and the peak
transmitral flow velocity may therefore be low.
There is no universally accepted method for dichotomizing
continuous variables. The cut-off points of continuous echo-
cardiographic measurements should be based on the distribu-
tion of these measurements in a randomly selected noninsti-
tutionalized sample of the general population.18,19 In the
present study, we selected a healthy subgroup from a general
population to propose cut-off limits for LV diastolic dysfunction.
Our age-specific percentiles of mitral E/A ratio are in close
agreement with previously reported age-specific thresholds from
the Tromsø population study (Supplemental Table B).14 In our
study, the 97.5th percentile of E/Ea ratio in the healthy subgroup
was 8.4. In previous invasive studies, an E/Ea ratio 8 accu-
rately indicated normal LV end-diastolic filling pressure.15 The
reference limit derived from our healthy reference subgroup for
the difference in duration between the mitral A flow and the
reverse PV flow (AdARd10) was less than in previous
studies of patients with coronary heart disease or cardiomyopa-
thy (AdARd30).20 However, the invasive study by
Yamamoto et al21 demonstrated that a difference between
A-wave and AR durations of less than 0 ms predicted a LV
end-diastolic pressure of 20 mm Hg or greater with high sensi-
tivity (82%) and specificity (92%).20
Cardiomyocytes produce BNP in response to an increase of
atrial or ventricular diastolic stretch to stimulate natriuresis
and vasodilatation and to facilitate LV relaxation.22 Secreted
proBNP is subsequently cleaved in the blood into NT-
proBNP and BNP. In patients with HF and normal EF, early
diastolic LV relaxation indexes correlate with NT-proBNP
values.22 NT-proBNP values also vary with the degree of LV
diastolic dysfunction. We observed progressively higher val-
ues in subjects with an impaired relaxation pattern (group 1),
and in subjects with elevated end-diastolic pressure (group 2).
However, in subjects with a combined dysfunction who had
an elevated E/Ea ratio and an abnormally low age-specific
E/A (group 3), NT-proBNP level was not different from
subjects with normal diastolic function. This finding highlights
the necessity to identify a panel of circulatory biomarkers which
might more accurately reflect diastolic dysfunction. We cannot
exclude the possibility that hitherto unidentified mechanisms,
such as a genetic variation in the generation or breakdown of
BNP might explain the findings in group 3.
Our study has to be interpreted within the context of its
potential limitations and strengths. First, the Doppler blood
flow measurements and the TDI velocities are quantitative
traits, which arise through a complex interaction between
multiple genes, hemodynamic and environmental factors and
are prone to measurement error, especially the Doppler
measurement of pulmonary flow. In the present study, only
one experienced observer recorded all Doppler images for
offline postprocessing. Second, our sample size was smaller
than in the Canberra4 and Olmsted3 studies. On the other
hand, we covered an age-range from 17.6 to 89.5 years (mean
age, 52.4 years). The age span in the Canberra and Olmsted
studies ranged from 60 to 86 years (mean age, 69.4 years) and
from 45 to 75 years and older (mean age, 62.8 years),
respectively. Third, we did not specifically score the symp-
toms and signs of HF. However, in a population based
research of 6 HF scores, Mosterd et al23 demonstrated that the
objective measurements of cardiac function are necessary to
reduce the false-positive rate and to detect in an accurate
manner the early stages of HF. We used the same detailed and
validated questionnaire6 at enrolment and at the echocardio-
graphic examination and checked for changes in the health
status of our subjects. All our participants were ambulatory
and physically apt to come to the examination center. More-
over, in continuous and categorical analyses, the correlates of
LV diastolic function were as expected and constitute an
internal validation of our study.
In conclusion, the overall prevalence of LV diastolic
dysfunction in a random sample of a general population, as
estimated from echocardiographic measurements and as con-
firmed by NT-proBNP level, was as high as 27.3%. Higher
age, body mass index, heart rate, systolic blood pressure,
serum insulin, and creatinine were significantly associated
with a higher risk of LV diastolic dysfunction in population.
Our findings have clinical relevance in view of the high risk
of overt HF in patients with impaired LV diastolic function.
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CLINICAL PERSPECTIVE
Because the process of myocardial remodeling starts before the onset of symptoms, recent heart failure guidelines place
special emphasis on the detection of subclinical left ventricular (LV) systolic and diastolic dysfunction and the timely
identification of risk factors for heart failure. Our goal was to describe the prevalence and risk factors of LV diastolic
dysfunction in a general population. In a randomly recruited population sample (n539; mean age, 52.5 years), we
measured early and late diastolic peak velocities of mitral inflow (E and A), pulmonary vein flow by pulsed-wave Doppler,
and mitral annular velocities (Ea and Aa) at 4 sites by tissue Doppler imaging. A healthy subsample of 239 subjects (mean
age, 43.7 years) provided age-specific cutoff limits for normal E/A and E/Ea ratios and the differences in duration between
the mitral A and the reverse pulmonary vein flows during atrial systole. The number of subjects in diastolic dysfunction
groups 1 (impaired relaxation), 2 (elevated LV end-diastolic filling pressure), and 3 (elevated E/Ea and abnormally low
E/A) were 53 (9.8%), 76 (14.1%), and 18 (3.4%), respectively. The overall prevalence of LV diastolic dysfunction in a
general population, as estimated from echocardiographic measurements and as confirmed by amino terminal probrain
natriuretic peptide level was 27.3%. Higher age, body mass index, heart rate, systolic blood pressure, serum insulin, and
creatinine were significantly associated with a higher risk of LV diastolic dysfunction in population. Our findings have
clinical relevance in view of the high risk of overt HF in patients with impaired LV diastolic function.
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      Supplemental Table A.  Transmitral E/A, averaged E/Ea and ∆(Adur–ARdur) in the Healthy Reference Group   
Age <30 30-39 40-49 50-59 ≥60 All   <30 30-39 40-49 50-59 ≥60 All  
E/A Ratio    ∆(Adur–ARdur) (ms)    
   N 45 36 81 53 24 239  45 35 80 51 23 234 
X 1.98 1.67 1.47 1.18 0.97 1.48  1.01 1.96 1.36 1.54 1.54 1.44 
SD 0.42 0.41 0.34 0.21 0.23 0.46  3.15 3.02 4.26 4.64 4.09 3.95 
P2.5 1.35 1.11 0.91 0.79 0.67 0.79  -5.71 -5.70 -5.71 -8.56 -7.13 -5.71 
P5 1.36 1.15 0.93 0.79 0.74 0.86  -2.85 -2.86 -4.99 -5.71 -5.71 -5.70 
P10 1.37 1.24 1.06 0.87 0.75 0.92  -2.85 -1.42 -2.86 -2.86 -4.22 -2.85 
P25 1.66 1.28 1.25 1.06 0.81 1.19  -1.42 0.00 -2.85 0.00 0.00 -1.42 
P50 1.96 1.61 1.40 1.22 0.89 1.39  1.42 1.43 1.42 1.42 1.43 1.42 
P75 2.33 1.97 1.67 1.31 1.12 1.70  2.85 4.29 4.28 4.27 5.70 4.27 
P90 2.45 2.14 1.93 1.47 1.28 2.08  4.28 5.71 7.85 7.13 5.71 5.71 
P95 2.53 2.50 2.03 1.51 1.41 2.43  5.71 7.13 9.27 8.55 6.90 8.56 
P97.5 2.87 2.82 2.26 1.55 1.55 2.51  5.71 8.56 9.98 8.56 8.56 8.57 
E/Ea Ratio 
   N 45 36 81 53 24 239 
X 5.07 5.63 6.02 6.47 6.89 5.97 
SD 0.91 1.06 1.25 1.19 0.94 1.25 
P2.5 3.84 3.49 3.65 4.49 4.38 3.84 
P5 3.93 3.64 4.32 4.62 5.11 4.01 
P10 4.04 4.55 4.54 4.92 5.82 4.47 
P25 4.40 4.84 5.09 5.50 6.30 5.01 
P50 4.93 5.56 6.01 6.45 7.06 5.96 
P75 5.35 6.30 6.84 7.13 7.54 6.81 
P90 6.25 7.17 7.56 8.09 7.93 7.64 
P95 6.78 7.47 8.29 8.61 8.05 8.09 
P97.5 6.86 8.26 8.52 8.75 8.21 8.39 
N, X, SD, P2.5, P5, P10, P25, P50, P75, P90, P95, P97.5  indicate number of subjects, mean, standard deviation and percentiles. 
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Supplemental Table B.  Age-specific Percentiles for the E/A Ratio in the Tromsø [15] and FLEMENGHO Studies.  
  2.5 percentile   97.5 percentile  
Age group (years)   Tromsø FLEMENGHO  Tromsø FLEMENGHO  
40-49   0.92 0.91  2.25 2.26  
  50-59   0.78 0.79  1.61 1.55  
>60    0.63 0.67  1.53  1.55  
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Supplemental Figure A   
 
 
Bland-Altman plots with the 95% limits of agreement for Ea and Aa velocities at 4 acquisition sites (septal, lateral, inferior, and posterior) 
(panels A and B) and for A-wave and pulmonary vein reversal A duration (panels C and D). Two observers analyzed the recordings of 
17 subjects. Absolute and relative biases between the 2 readers were calculated as (x1 – x2) vs averaged and (100*(x1 – x2)/averaged) 
vs averaged, respectively.  
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